Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionPlace of product in therapyDisease description

Natural history, survival, and mortality

17 evidence topics · 19 sources

U.S. 5-year relative survival by stage at diagnosis, SEER 21, 2016 to 2022
Stage at diagnosis5-year relative survival
Localized“100.0%”
Regional“87.5%”
Distant“33.8%”